Stern Investor Relations parent company, Precision Medicine Group, announced that it has completed a major investment and recapitalization led by funds managed by Blackstone, with significant participation from Precision’s co-founders, as well as current shareholders Berkshire Partners, TPG Growth, Oak HC/FT and Vida Ventures. This investment will help fuel the expansion of PMG’s global footprint and technical capabilities to help accelerate the development, approval and commercial reach of breakthrough therapies from life science innovators. We are thrilled to welcome Blackstone to the PMG family, and look forward to their partnership!
Full press release: Precision Medicine Group Secures Major Investment from Blackstone | Precision Medicine Group (precisionmedicinegrp.com)